296 related articles for article (PubMed ID: 25831493)
1. Cross-talk between PKA-Cβ and p65 mediates synergistic induction of PDE4B by roflumilast and NTHi.
Susuki-Miyata S; Miyata M; Lee BC; Xu H; Kai H; Yan C; Li JD
Proc Natl Acad Sci U S A; 2015 Apr; 112(14):E1800-9. PubMed ID: 25831493
[TBL] [Abstract][Full Text] [Related]
2. Dexamethasone Inhibits Synergistic Induction of PDE4B Expression by Roflumilast and Bacterium NTHi.
Lee BC; Susuki-Miyata S; Yan C; Li JD
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30413022
[TBL] [Abstract][Full Text] [Related]
3. PDE4 inhibition reduces neointima formation and inhibits VCAM-1 expression and histone methylation in an Epac-dependent manner.
Lehrke M; Kahles F; Makowska A; Tilstam PV; Diebold S; Marx J; Stöhr R; Hess K; Endorf EB; Bruemmer D; Marx N; Findeisen HM
J Mol Cell Cardiol; 2015 Apr; 81():23-33. PubMed ID: 25640159
[TBL] [Abstract][Full Text] [Related]
4. The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation.
Konrad FM; Bury A; Schick MA; Ngamsri KC; Reutershan J
PLoS One; 2015; 10(4):e0121725. PubMed ID: 25909327
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase-4 inhibition augments human lung fibroblast vascular endothelial growth factor production induced by prostaglandin E2.
Ikari J; Michalski JM; Iwasawa S; Gunji Y; Nogel S; Park JH; Nelson AJ; Farid M; Wang X; Schulte N; Basma H; Toews ML; Feghali-Bostwick C; Tenor H; Liu X; Rennard SI
Am J Respir Cell Mol Biol; 2013 Oct; 49(4):571-81. PubMed ID: 23656623
[TBL] [Abstract][Full Text] [Related]
6. Glucocorticoid Receptor α Mediates Roflumilast's Ability to Restore Dexamethasone Sensitivity in COPD.
Reddy AT; Lakshmi SP; Banno A; Reddy RC
Int J Chron Obstruct Pulmon Dis; 2020; 15():125-134. PubMed ID: 32021151
[TBL] [Abstract][Full Text] [Related]
7. PDE4 inhibitor, roflumilast protects cardiomyocytes against NO-induced apoptosis via activation of PKA and Epac dual pathways.
Kwak HJ; Park KM; Choi HE; Chung KS; Lim HJ; Park HY
Cell Signal; 2008 May; 20(5):803-14. PubMed ID: 18276108
[TBL] [Abstract][Full Text] [Related]
8. Roflumilast inhibits leukocyte-platelet interactions and prevents the prothrombotic functions of polymorphonuclear leukocytes and monocytes.
Totani L; Amore C; Di Santo A; Dell'Elba G; Piccoli A; Martelli N; Tenor H; Beume R; Evangelista V
J Thromb Haemost; 2016 Jan; 14(1):191-204. PubMed ID: 26484898
[TBL] [Abstract][Full Text] [Related]
9. Direct Inhibitory Effect of the PDE4 Inhibitor Roflumilast on Neutrophil Migration in Chronic Obstructive Pulmonary Disease.
Dunne AE; Kawamatawong T; Fenwick PS; Davies CM; Tullett H; Barnes PJ; Donnelly LE
Am J Respir Cell Mol Biol; 2019 Apr; 60(4):445-453. PubMed ID: 30395484
[TBL] [Abstract][Full Text] [Related]
10. The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease.
Cazzola M; Calzetta L; Rogliani P; Matera MG
Expert Opin Drug Discov; 2016 Jul; 11(7):733-44. PubMed ID: 27169612
[TBL] [Abstract][Full Text] [Related]
11. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiestrase-1 and 4 inhibitors ameliorate liver fibrosis in rats: Modulation of cAMP/CREB/TLR4 inflammatory and fibrogenic pathways.
Essam RM; Ahmed LA; Abdelsalam RM; El-Khatib AS
Life Sci; 2019 Apr; 222():245-254. PubMed ID: 30858122
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.
Lipworth BJ
Lancet; 2005 Jan 8-14; 365(9454):167-75. PubMed ID: 15639300
[TBL] [Abstract][Full Text] [Related]
14. A phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma.
Suhasini AN; Wang L; Holder KN; Lin AP; Bhatnagar H; Kim SW; Moritz AW; Aguiar RCT
Leukemia; 2016 Mar; 30(3):617-626. PubMed ID: 26503641
[TBL] [Abstract][Full Text] [Related]
15. Roflumilast N-oxide inhibits bronchial epithelial to mesenchymal transition induced by cigarette smoke in smokers with COPD.
Milara J; Peiró T; Serrano A; Guijarro R; Zaragozá C; Tenor H; Cortijo J
Pulm Pharmacol Ther; 2014 Aug; 28(2):138-48. PubMed ID: 24525294
[TBL] [Abstract][Full Text] [Related]
16. Exploring the Role of Water Molecules in the Ligand Binding Domain of PDE4B and PDE4D: Virtual Screening Based Molecular Docking of Some Active Scaffolds.
Singh P; Mishra M; Agarwal S; Sau S; Iyer AK; Kashaw SK
Curr Comput Aided Drug Des; 2019; 15(4):334-366. PubMed ID: 30394213
[TBL] [Abstract][Full Text] [Related]
17. Roflumilast ameliorates cognitive impairment in APP/PS1 mice via cAMP/CREB/BDNF signaling and anti-neuroinflammatory effects.
Feng H; Wang C; He W; Wu X; Li S; Zeng Z; Wei M; He B
Metab Brain Dis; 2019 Apr; 34(2):583-591. PubMed ID: 30610438
[TBL] [Abstract][Full Text] [Related]
18. The potential role of roflumilast: the new phosphodiesterase-4 inhibitor.
Karish SB; Gagnon JM
Ann Pharmacother; 2006 Jun; 40(6):1096-104. PubMed ID: 16735669
[TBL] [Abstract][Full Text] [Related]
19. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
Cooney JD; Lin AP; Jiang D; Wang L; Suhasini AN; Myers J; Qiu Z; Wölfler A; Sill H; Aguiar RCT
Clin Cancer Res; 2018 Mar; 24(5):1103-1113. PubMed ID: 29246942
[No Abstract] [Full Text] [Related]
20. A Nonhuman Primate PET Study: Measurement of Brain PDE4 Occupancy by Roflumilast Using (R)-[
Takano A; Uz T; Garcia-Segovia J; Tsai M; Lahu G; Amini N; Nakao R; Jia Z; Halldin C
Mol Imaging Biol; 2018 Aug; 20(4):615-622. PubMed ID: 29441434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]